Sean Kerby, MD
Family Medicine · Gulfport, MSNPI 1730268939
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.0%), travel and lodging and education — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Modernatx, Inc. at 54.8% of the total. Reporting peaked in 2023 at $3,941 and has fallen 91.1% since, to $350 in 2025. Among family medicine clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 185 payments — averaging $34.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$4K
- Merck$443
- Lilly USA, LLC$396
- Amgen$353
- Pfizer$235
- Novo Nordisk$224
- plus $1K from 23 others
Across 3,849 payments — averaging $1710.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$6.6M
What the payments were for
- Travel & lodging$2,95646%
- Food & beverage$3,48254%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 7 | $3,536 |
| Merck | 25 | $443 |
| Lilly USA, LLC | 22 | $396 |
| Amgen | 22 | $353 |
| Pfizer | 18 | $235 |
| Novo Nordisk | 14 | $224 |
| GSK | 12 | $181 |
| Novartis | 7 | $146 |
| AbbVie(2 entities) | 7 | $136 |
| Johnson & Johnson | 8 | $107 |
| Esperion Therapeutics, Inc. | 6 | $105 |
| Kowa Pharmaceuticals America, Inc. | 6 | $88 |
| Amarin Pharma, Inc. | 5 | $81 |
| Boehringer Ingelheim | 4 | $60 |
| AstraZeneca | 4 | $57 |
| Abbott | 2 | $42 |
| Endo Pharmaceuticals Inc. | 2 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Exact Sciences | 2 | $27 |
| Shield Therapeutics Inc | 1 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Eisai Inc. | 1 | $18 |
| Mylan Specialty L.p. | 1 | $18 |
| Bayer | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $15 |
| PBG Puerto Rico LLC | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
How this compares
$6,452 in reported general payments places this provider in the 90th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 60 | $65,747 |
| JanuviaSitagliptin Phosphate | 48 | $43,734 |
| JardianceEmpagliflozin | 38 | $17,068 |
| EliquisApixaban | 30 | $15,694 |
| TradjentaLinagliptin | 16 | $12,466 |
| MounjaroTirzepatide | 11 | $10,776 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $7,096 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,648 |
| Ezetimibe | 211 | $4,646 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 25 | $3,972 |
| Rosuvastatin Calcium | 364 | $3,933 |
| Atorvastatin Calcium | 474 | $2,736 |
| SynthroidLevothyroxine Sodium | 39 | $2,689 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 60 | $2,657 |
| Pravastatin Sodium | 150 | $2,625 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $224 | $65,74760 claims |
| MerckJanuvia | $443 | $43,73448 claims |
| Boehringer IngelheimJardiance, Tradjenta | $60 | $29,53454 claims |
| PfizerEliquis | $235 | $15,69430 claims |
| Lilly USA, LLCMounjaro | $396 | $10,77611 claims |
| AstraZenecaSymbicort | $57 | $7,09622 claims |
| GSKBreo Ellipta | $181 | $4,64812 claims |
| AbbVieSynthroid | $136 | $2,68939 claims |
| NovartisEntresto | $146 | $2,24611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Gulfport
- Kathy KeimigGulfport$20K
- Jonathan HamiltonGulfport$16K
- Dimitrios DimitriadesGulfport$13K
- Steven SchepensGulfport$12K
- Matthew BosargeGulfport$10K
- Paul MatherneGulfport$9K
- Russell CarlisleWesson$1.6M
- Keith StokesLexington$654K
- Walter CarnahanSouthaven$146K
- Karen WhitneyWhitfield$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.